Udo Werner becomes CFO of CyBio AG
CyBio AG announced the appointment of Mr. Udo Werner as a member of the Company's Executive Management Board responsible for Finance and logistics. Mr. Werner will start his new position on October 1, 2009.
The 42 year old lawyer and Harvard graduate was CFO at the Erfurt-based TechnoTrend AG and later became Chief Operating Officer and member of the Executive Management Board at its Dutch parent company TechnoTrend Holding NV. His responsibilities further included corporate strategy, M&A activities, HR and Legal Affairs. Before joining TechnoTrend Mr. Werner held several positions at McKinsey & Co., Inc.
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Emerging gene editing approach seeks broad spectrum crop disease resistance

New biologically derived metal-organic framework mimics DNA

Scientists identify rare gene variants which confer up to 6-fold increase in risk of obesity - Genetic variants reveal new biological mechanism regulating appetite control
Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing

Applied Analytics, Inc. - Burlington, USA

New solution for stem cell manufacturing - A unique 3D printed system for harvesting stem cells from bioreactors
Specialist Business Unit of the University of Nottingham Spins-Out to Form New R&D Oncology Company
Increasing Interest in Cholesterol-lowering Treatment Drive Phytosterol Sales
